Endomyocardial Biopsy Market Forecast to Grow from USD 318.03 Million to USD 599.52 Million
Endomyocardial Biopsy Market to Reach USD 599.52 million by 2032, Growing at 6.6% CAGR: Polaris Market Research
Polaris Market Research has published its latest analysis of the global Endomyocardial Biopsy Market, which is projected to expand from USD 338.13 million in 2023 to USD 599.52 million by 2032, representing a 6.6% CAGR during 2023-2032. The report profiles 7 leading companies and evaluates 3 core segmentation dimensions, in addition to regional performance.
Market Growth Commentary on the Endomyocardial Biopsy Market
Demand for endomyocardial biopsy procedures is being reinforced by the growing burden of cardiovascular disease and by rising heart-transplant volumes. The procedure remains an important tool for monitoring transplanted hearts and detecting rejection, while improved forceps, imaging support and ambulatory-care options can increase procedural precision and accessibility.
Endomyocardial Biopsy Market Statistics at a Glance
- 2023 Market Size: USD 338.13 million
- 2032 Projected Size: USD 599.52 million
- CAGR (2023-2032): 6.6%
- Leading Region (2022): North America
- Growth Region: Asia Pacific
Key Growth Drivers, Major Companies and Segments Covered
Growth Drivers: rising prevalence of cardiovascular diseases and the need for accurate tissue-based diagnosis; growth in heart-transplant procedures, where biopsy is used to monitor rejection; advances in minimally invasive diagnostic technologies and wider access to specialized cardiac care. These factors are shaping market growth, investment priorities and product development across the forecast period.
Major Companies Covered: Argon Medical, Cordis, Mermaid Medical, Terumo Corp., Scholten Surgicals, among others.
Segments Covered: By Product (Forceps; Accessories), By Tip (Maxi-curved; Straight; Pre-curved; Others), By End Use (Hospitals; Ambulatory Surgical Centers; Others), and By Region.
👉 Download a Free Sample of the Endomyocardial Biopsy Market Report → https://www.polarismarketresearch.com/industry-analysis/endomyocardial-biopsy-market
Recent Developments in the Endomyocardial Biopsy Market
- May 2022: Terumo Corp. signed a partnership agreement with Argon Medical focused on supporting advanced diagnosis and treatment needs.
Regional Snapshot: North America Leads; Asia Pacific Shows Expansion Potential
North America dominated the market in 2022, supported by established healthcare infrastructure, high healthcare spending, adoption of minimally invasive procedures, and the presence of major medical-device companies. Asia Pacific is expected to grow fastest, aided by rising cardiovascular disease prevalence, healthcare investment, and a large aging population.
Why It Matters for Healthcare Buyers Evaluating Endomyocardial Biopsy Market Opportunities
For stakeholders researching healthcare buyers evaluating endomyocardial biopsy market opportunities, the underlying Polaris Market Research report benchmarks Endomyocardial Biopsy Market size, competitive positioning, market share trends, segmentation and regional dynamics through 2032. The analysis can support supplier screening, product strategy, partnership assessment, market-entry planning and investment decisions by connecting demand drivers with the companies, applications and geographies shaping the industry.
About Polaris Market Research
Polaris Market Research is a B2B syndicated market research and consulting firm offering 5,000+ published reports across 20+ industry verticals, delivering data-backed insights to help businesses make informed decisions.
More Trending Latest Reports By Polaris Market Research:
Automotive Oil Recycling Market
- Art
- Causes
- Crafts
- Dance
- Drinks
- Film
- Fitness
- Food
- Games
- Gardening
- Health
- Home
- Literature
- Music
- Networking
- Other
- Party
- Religion
- Shopping
- Sports
- Theater
- Wellness
